

SAFETY DATA SHEETS

This SDS packet was issued with item:

078929357

N/A

SAFETY DATA SHEET



1. Identification

Product identifier Fluvac Innovator 4

Other means of identification

Synonyms

Fluvac Innovator® 4 * FLUVAC® INNOVATOR 4 * Fluvac Innovator EWT *
Encephalomyelitis-Influenza Vaccine, Eastern & Western, Killed Virus, Tetanus Toxoid

Recommended use

Veterinary vaccine

Recommended restrictions

Not for human use

Manufacturer/Importer/Supplier/Distributor information

Company Name (USA)

Zoetis Inc.
10 Sylvan Way
Parsippany, New Jersey 07054 (USA)

**Rocky Mountain Poison
and Drug Center**

1-866-531-8896

**Product Support/Technical
Services**

1-800-366-5288

**Emergency telephone
numbers**

CHEMTREC (24 hours): 1-800-424-9300

International CHEMTREC (24 hours): +1-703-527-3887

Company Name (CA)

Zoetis Canada Inc.
16740 Trans-Canada Highway
Kirkland, Quebec, H9H 4M7

**Emergency telephone
number**

International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail

productsupport@zoetis.com

Product Support

1-800-461-0917

All Safety Data Sheets are available via our Zoetis Canada website at
<https://www.zoetis.ca/sds/sds.aspx>

Supplier

Not available.

2. Hazard(s) identification

Physical hazards

Not classified.

Health hazards

Not classified.

Environmental hazards

Not classified.

Label elements

Hazard symbol

None.

Signal word

None.

Hazard statement

The mixture does not meet the criteria for classification.

Precautionary statement

Prevention

Observe good industrial hygiene practices.

Response

Wash hands after handling.

Storage

Store away from incompatible materials.

Disposal

Dispose of waste and residues in accordance with local authority requirements.

Other hazards

None known.

Supplemental information

Direct contact with eyes may cause temporary irritation. In the event of accidental injection, an allergic reaction may occur. This product is an oil-adjuvanted suspension. Oil-adjuvant containing products may cause severe vasospasm following accidental injection.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Squalene		111-02-4	<10
Clostridium tetani toxoid		Not assigned	*
EASTERN EQUINE ENCEPHALOMYELITIS		Not assigned	*
Equine Influenza Virus, Kentucky 97 (EIV)		Not assigned	*
Neomycin B		119-04-0	##
Polymyxin B		1404-26-8	##
Sodium O-(ethylmercurithio)benzoate		54-64-8	##
WESTERN EQUINE ENCEPHALOMYELITIS		Not assigned	*

All concentrations are in percent by weight unless ingredient is a gas. Gas concentrations are in percent by volume.

Composition comments ## Trace
* Non-hazardous Ingredients

4. First-aid measures

Inhalation	Move to fresh air. Call a physician if symptoms develop or persist.
Skin contact	In the case of skin contact, immediately wash the skin with plenty of soap and water. In the event of accidental self injection or needle stick injury, wash the injury thoroughly with clean running water. Get medical attention immediately.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. Remove contact lenses, if present and easy to do.
Ingestion	Rinse mouth. Call a physician or poison control centre immediately. Only induce vomiting at the instruction of medical personnel. Never give anything by mouth to an unconscious person.
Most important symptoms/effects, acute and delayed	Direct contact with eyes may cause temporary irritation. Exposure may cause temporary irritation, redness, or discomfort. In the event of accidental injection, an allergic reaction may occur. Signs and symptoms might include skin rash, itching, redness or swelling. Respiratory reactions may be characterized by rhinitis, sneezing, scratchy throat, oral mucosal edema, laryngeal mucosal edema, coughing, shortness of breath, wheezing, and chest pain. Asthma like reactions occur with acute exposures in sensitized patients. This product is an oil-adjuvanted suspension. Oil-adjuvant containing products may cause severe vasospasm following accidental injection.
Indication of immediate medical attention and special treatment needed	Treat symptomatically. Where parenteral oil-adjuvanted vaccine exposure has occurred, the patient should be promptly evaluated for the development of vasospasm and/or compartment syndrome.
General information	For personal protection, see section 8 of the SDS. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

5. Fire-fighting measures

Suitable extinguishing media	Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).
Unsuitable extinguishing media	Do not use water jet as an extinguisher, as this will spread the fire.
Specific hazards arising from the chemical	During fire, gases hazardous to health may be formed.
Special protective equipment and precautions for firefighters	Self-contained breathing apparatus and full protective clothing must be worn in case of fire.
Fire fighting equipment/instructions	Move containers from fire area if you can do so without risk.
Specific methods	Use standard firefighting procedures and consider the hazards of other involved materials.
General fire hazards	No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures	Keep unnecessary personnel away. For personal protection, see section 8 of the SDS.
--	---

Methods and materials for containment and cleaning up

Large Spills: Stop the flow of material, if this is without risk. Cover with plastic sheet to prevent spreading. Absorb in vermiculite, dry sand or earth and place into containers. Following product recovery, flush area with water.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use. For waste disposal, see section 13 of the SDS. Avoid discharge into drains, water courses or onto the ground.

Environmental precautions**7. Handling and storage****Precautions for safe handling**

Avoid contact with eyes, skin, and clothing. Avoid breathing mist or vapour. Avoid accidental injection. Wash thoroughly after handling. When using, do not eat, drink or smoke. Wear personal protective equipment. Avoid release to the environment. Observe good industrial hygiene practices.

Conditions for safe storage, including any incompatibilities

Store out of direct sunlight in dark, dry conditions. @ 2 - 7°C (36 - 45°F). Do not freeze. Store in original tightly closed container. Keep away from heat, sparks and open flame. Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection**Occupational exposure limits****Zoetis****Components****Type****Value**

Neomycin B (CAS 119-04-0)

TWA

100 µg/m³

**US. ACGIH Threshold Limit Values
Components****Type****Value**

Sodium
O-(ethylmercurithio)benzoate (CAS 54-64-8)

STEL

0.03 mg/m³

TWA

0.01 mg/m³

Canada. Alberta OELs (Occupational Health & Safety Code, Schedule 1, Table 2)**Components****Type****Value**

Sodium
O-(ethylmercurithio)benzoate (CAS 54-64-8)

STEL

0.03 mg/m³

TWA

0.01 mg/m³

Canada. British Columbia OELs. (Occupational Exposure Limits for Chemical Substances, Occupational Health and Safety Regulation 296/97, as amended)**Components****Type****Value**

Sodium
O-(ethylmercurithio)benzoate (CAS 54-64-8)

STEL

0.03 mg/m³

TWA

0.01 mg/m³

Canada. Manitoba OELs (Reg. 217/2006, The Workplace Safety And Health Act)**Components****Type****Value**

Sodium
O-(ethylmercurithio)benzoate (CAS 54-64-8)

STEL

0.03 mg/m³

TWA

0.01 mg/m³

Canada. Ontario OELs. (Control of Exposure to Biological or Chemical Agents)**Components****Type****Value**

Sodium
O-(ethylmercurithio)benzoate (CAS 54-64-8)

STEL

0.03 mg/m³

TWA

0.01 mg/m³

Canada. Quebec OELs. (Ministry of Labour - Regulation Respecting the Quality of the Work Environment)

Components	Type	Value
Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8)	STEL	0.03 mg/m3
	TWA	0.01 mg/m3

Biological limit values No biological exposure limits noted for the ingredient(s).

Exposure guidelines**Canada - Alberta OELs: Skin designation**

Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8) Can be absorbed through the skin.

Canada - British Columbia OELs: Skin designation

Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8) Can be absorbed through the skin.

Canada - Manitoba OELs: Skin designation

Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8) Can be absorbed through the skin.

Canada - Ontario OELs: Skin designation

Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8) Can be absorbed through the skin.

Canada - Quebec OELs: Skin designation

Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8) Can be absorbed through the skin.

Canada - Saskatchewan OELs: Skin designation

Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8) Can be absorbed through the skin.

US ACGIH Threshold Limit Values: Skin designation

Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8) Can be absorbed through the skin.

Control banding approach Polymyxin B: Zoetis OEB 2 - Sensitizer (control exposure to the range of 100ug/m3 to < 1000ug/m3, provide additional precautions to protect from skin contact)

Appropriate engineering controls Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. General ventilation normally adequate.

Individual protection measures, such as personal protective equipment

Eye/face protection If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection Wear impervious gloves if skin contact is possible.

Other Wear suitable protective clothing. Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.

Respiratory protection No personal respiratory protective equipment normally required. In case of insufficient ventilation, wear suitable respiratory equipment. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

Thermal hazards Not applicable.

General hygiene considerations Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

9. Physical and chemical properties**Appearance**

Physical state Liquid.

Form Liquid.

Colour Pink to milky red

Odour Not available.

Odour threshold Not available.

pH Not available.

Melting point/freezing point Not available.

Initial boiling point and boiling range Not available.

Flash point Non-flammable

Evaporation rate	Not available.
Flammability (solid, gas)	Not applicable.
Upper/lower flammability or explosive limits	
Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Explosive limit - lower (%)	Not available.
Explosive limit – upper (%)	Not available.
Vapour pressure	Not available.
Vapour density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Not available.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Other information	
Explosive properties	Not explosive.
Oxidising properties	Not oxidising.

10. Stability and reactivity

Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	Contact with incompatible materials. Sunlight. Store at 2-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
Incompatible materials	Strong oxidising agents. This material can be denatured or inactivated by a variety of organic solvents, salts or heavy metals.
Hazardous decomposition products	No hazardous decomposition products are known.

11. Toxicological information

Information on likely routes of exposure

Inhalation	No adverse effects due to inhalation are expected.
Skin contact	Prolonged skin contact may cause temporary irritation.
Eye contact	Direct contact with eyes may cause temporary irritation.
Sodium O-(ethylmercurithio)benzoate	
Species: Rabbit	
Severity: Mild	

Ingestion	Expected to be a low ingestion hazard.
------------------	--

Symptoms related to the physical, chemical and toxicological characteristics	Direct contact with eyes may cause temporary irritation. Exposure may cause temporary irritation, redness, or discomfort. In the event of accidental injection, an allergic reaction may occur. Signs and symptoms might include skin rash, itching, redness or swelling. Respiratory reactions may be characterized by rhinitis, sneezing, scratchy throat, oral mucosal edema, laryngeal mucosal edema, coughing, shortness of breath, wheezing, and chest pain. Asthma like reactions occur with acute exposures in sensitized patients.
---	---

Information on toxicological effects

Acute toxicity

Components	Species	Test results
Neomycin B (CAS 119-04-0)		
<u>Acute</u>		
Intravenous		
LD50	Mouse	24 mg/kg
Oral		
LD50	Rat	1250 mg/kg
Polymyxin B (CAS 1404-26-8)		
<u>Acute</u>		
Oral		
LD50	Mouse	790 mg/kg
Other		
LD50	Mouse	3980 ug/kg
Subcutaneous		
LD50	Rat	50 mg/kg
Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8)		
<u>Acute</u>		
Oral		
LD50	Mouse	91 mg/kg
	Rat	75 mg/kg
Subcutaneous		
LD50	Rat	98 mg/kg
Skin corrosion/irritation	Prolonged skin contact may cause temporary irritation.	
Serious eye damage/eye irritation	Direct contact with eyes may cause temporary irritation.	
Eye contact		
Sodium O-(ethylmercurithio)benzoate	Species: Rabbit	Severity: Mild
Respiratory or skin sensitisation		
Respiratory sensitisation	Not a respiratory sensitizer.	
Skin sensitisation	This product contains merthiolate which is considered to be a skin sensitizer. This product is not expected to cause skin sensitisation.	
Germ cell mutagenicity	No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.	
Mutagenicity		
Polymyxin B	In vitro	Result: negative
	In vivo	Result: negative
Carcinogenicity	This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA.	
Reproductive toxicity	This product is not expected to cause reproductive or developmental effects.	
Specific target organ toxicity - single exposure	Not classified.	
Specific target organ toxicity - repeated exposure	Not classified.	
Aspiration hazard	Not an aspiration hazard.	
Further information	Allergic reactions are possible. The antigens included in this product are non-infectious. All have been prepared from killed or inactivated preparations of microorganisms. This product is an oil-adjuvanted suspension. Oil-adjuvant containing products may cause severe vasospasm following accidental injection.	

12. Ecological information

Ecotoxicity	The product is not classified as environmentally hazardous. However, this does not exclude the possibility that large or frequent spills can have a harmful or damaging effect on the environment. Avoid release to the environment.
Persistence and degradability	No data is available on the degradability of this product.
Bioaccumulative potential	No data available.
Mobility in soil	No data available.
Other adverse effects	No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Disposal instructions	Avoid release to the environment. Do not discharge into drains, water courses or onto the ground. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. Dispose of contents/container in accordance with local/regional/national/international regulations.
Local disposal regulations	Dispose in accordance with all applicable regulations.
Hazardous waste code	The waste code should be assigned in discussion between the user, the producer and the waste disposal company. This product contains trace quantities of mercury, releases to the environment should be avoided.
Waste from residues / unused products	Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).
Contaminated packaging	Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport information

TDG	Not regulated as dangerous goods.
IATA	Not regulated as dangerous goods.
IMDG	Not regulated as dangerous goods.
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code	Not established.

15. Regulatory information

Canadian regulations	This product has been classified in accordance with the hazard criteria of the HPR and the SDS contains all the information required by the HPR.	
Controlled Drugs and Substances Act		
Not regulated.		
Export Control List (CEPA 1999, Schedule 3)		
Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8)		Substance subject to notification or consent.
Greenhouse Gases		
Not listed.		
Ontario. Toxic Substances. Toxic Reduction Act, 2009. Regulation 455/09 (July 1, 2011)		
Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8)		
Precursor Control Regulations		
Not regulated.		
International regulations		
Stockholm Convention		
Not applicable.		
Rotterdam Convention		
Sodium O-(ethylmercurithio)benzoate (CAS 54-64-8)		Pesticide
Kyoto protocol		
Not applicable.		

Montreal Protocol

Not applicable.

Basel Convention

Not applicable.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information

Issue date	16-April-2017
Version No.	01
Disclaimer	Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. The information in the sheet was written based on the best knowledge and experience currently available.
Revision information	Product and Company Identification: Synonyms Composition / Information on Ingredients: Ingredients Physical & Chemical Properties: Multiple Properties